Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hope O'Brien

Neurology with Special Qualifications in Child Neurology Cincinnati, OH Medical Doctor

NPI 1972704138 CMS profile 647248

3333 Burnet Ave Ml 2015, Cincinnati, OH 45229

Open in the dashboard

General payments

$524,674

602 records reported · program years 2019–2025

Research payments

$32,294

Paid to them · 10 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$463,486 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Hope O'Brien of Cincinnati, OH is reported in the CMS Open Payments database as having received $524,674 across 602 general payments and $32,294 in research payments paid to them. Separately, studies naming them as principal investigator received $463,486 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $116,352 125
2024 General $166,883 152
2024 Research $11,400 3
2023 General $116,597 166
2023 Research $2,501 3
2022 General $60,780 72
2022 Research $18,393 4
2021 General $60,446 83
2020 General $1,214 3
2019 General $2,400 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hope O'Brien
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Hope O'Brien were reported at $116,352. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Hope O'Brien Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $2,400 $262 $68–$1,313 $163
2020 $1,214 $188 $46–$1,222 $114
2021 $60,446 $183 $45–$1,356 $132
2022 $60,780 $229 $72–$1,177 $149
2023 $116,597 $269 $93–$1,195 $160
2024 $166,883 $300 $98–$1,428 $164
2025 $116,352 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $202,636 229 payments
  2. Pfizer Inc. $114,732 96 payments
  3. Lilly USA, LLC $77,289 107 payments
  4. Biohaven Pharmaceuticals, Inc. $45,818 46 payments
  5. Biohaven Pharmaceutical Holding Company Ltd. $23,850 23 payments
  6. Axsome Therapeutics, Inc. $15,571 18 payments
  7. Biodelivery Sciences International, Inc. $12,020 14 payments
  8. Amgen Inc. $10,537 8 payments
  9. Eli Lilly and Company $10,343 14 payments
  10. Bausch Health US, LLC $4,125 3 payments
  11. Other $7,753 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $286,429 93 payments
  2. Consulting Fee $153,115 53 payments
  3. Travel and Lodging $42,774 136 payments
  4. Honoraria $25,865 9 payments
  5. Food and Beverage $16,456 306 payments
  6. Education $35 5 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $116,819 122 payments
  2. QULIPTA $111,609 129 payments
  3. NURTEC ODT Primary Care $69,669 69 payments
  4. NURTEC ODT Pain $54,878 57 payments
  5. ZAVZPRET $36,337 37 payments
  6. EMGALITY $15,560 29 payments
  7. Symbravo $15,524 16 payments
  8. AIMOVIG $10,537 8 payments
  9. ELYXYB - CELECOXIB Pain Management $7,799 10 payments
  10. ELYXYB - celecoxib Migraine $5,127 5 payments
  11. Other $13,590 75 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $19,954 6 payments
  2. AbbVie, Inc. $8,200 2 payments
  3. Pfizer Inc. $4,140 2 payments

Records

612 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record